Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs

Sep.10
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.

Key Points

  • USSTC broke ground on the roughly $250 million Hopkinsville project on September 8.
  • The new facility will cover about 270,000 square feet and is expected to add more than 200 jobs.
  • The project will consolidate some processing, manufacturing and packaging operations currently spread between Hopkinsville and Nashville.
  • Production at the Nashville facility is expected to wind down by early 2028 as Altria modernizes its manufacturing footprint.

2Firsts

September 10, 2026

According to The Lane Report and local media on September 8, U.S. Smokeless Tobacco Company, an Altria Group operating company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky.

The project will add roughly 270,000 square feet at USSTC’s existing Hopkinsville site, create more than 200 jobs and absorb parts of the processing, manufacturing and packaging work currently handled in Nashville, Tennessee.

USSTC Is a Core Altria Smokeless Tobacco Business

USSTC is one of Altria’s operating companies and produces moist smokeless tobacco brands including Copenhagen, Skoal, Red Seal and Husky.

Altria acquired USSTC in 2009 and incorporated the business into its U.S. tobacco operations.

The Hopkinsville investment is therefore part of a broader Altria manufacturing strategy rather than a standalone expansion by an independent company.

USSTC already operates tobacco-processing activities in Hopkinsville. The new facility will expand the site and consolidate operations now divided between Hopkinsville and Nashville.

$250 Million Project to Add More Than 200 Jobs

The total investment is expected to be about $250 million.

The new facility will span approximately 270,000 square feet and is expected to create more than 200 jobs.

Kentucky officials have previously said the project could roughly double USSTC’s workforce in the state once fully implemented.

Kentucky Governor Andy Beshear also attended events surrounding the project and highlighted the investment as part of the state’s manufacturing and employment growth.

Hopkinsville to Absorb Nashville Production

USSTC announced in May 2026 that it planned to gradually transfer manufacturing operations from its Nashville facility to Hopkinsville.

The Nashville plant covers roughly 800,000 square feet and employs more than 300 people. It handles portions of post-processing and packaging for brands including Copenhagen, Skoal, Red Seal and Husky.

Under the company’s plan, production in Nashville is expected to wind down by early 2028.

Operations will be consolidated in Hopkinsville, while the Nashville property is expected to be sold after production ends.

The Hopkinsville project therefore represents not simply new capacity, but a restructuring of Altria’s U.S. smokeless tobacco manufacturing network.

Altria Says Move Will Improve Efficiency and Resilience

Altria has said concentrating operations in Hopkinsville is expected to reduce fixed costs, improve efficiency and strengthen manufacturing resilience.

The project will bring processing, production and packaging operations that were previously spread across multiple locations into a more consolidated footprint.

For the traditional smokeless tobacco business, that can reduce cross-site complexity and duplicated infrastructure.

The investment also shows that while Altria continues to expand into nicotine pouches, vaping and other smoke-free categories, it is still committing significant capital to modernize its established moist smokeless tobacco operations.

Distinct From Altria’s Other Smoke-Free Platforms

Altria’s smoke-free portfolio extends beyond USSTC.

The group also operates the on! and on! PLUS nicotine pouch business through Helix Innovations, owns NJOY in vaping, and is pursuing heated tobacco-related opportunities.

The Hopkinsville project, however, relates specifically to USSTC’s traditional smokeless tobacco manufacturing operations, not nicotine pouch or vaping production.

That distinction matters.

In U.S. regulatory and corporate usage, “smokeless tobacco” includes traditional tobacco-containing products such as moist smokeless tobacco and should not automatically be treated as synonymous with newer tobacco-free oral nicotine products.

Manufacturing Consolidation Is the Core of the Project

From Altria’s broader manufacturing perspective, the central purpose of the Hopkinsville expansion is the consolidation of USSTC’s existing production footprint rather than the launch of a new product category.

As Nashville production is phased out, Hopkinsville is set to become a more important manufacturing hub within USSTC’s network.

For Altria, the project brings together capacity reallocation, fixed-cost reduction and long-term infrastructure investment in its traditional smokeless tobacco business.

The expansion is expected to progress over the next two years, in line with the company’s plan to wind down Nashville production by early 2028.

Follow 2Firsts for timely updates on global tobacco and nicotine industry developments, corporate strategy and market trends.

Cover Image: christiancountynow


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%
How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%
Logista France says tobacco consumption outside France’s official tobacconist network has become a large and structural market phenomenon, but official and industry estimates differ sharply. France’s TAFE study estimates that 17.7% of tobacco consumption escaped domestic taxation in 2023, with most of that volume attributed to cross-border purchasing rather than street sales. Some industry studies use broader off-channel definitions and put the figure above 50%. Meanwhile, French Customs seized 547.94 tonnes of tobacco in 2025, up 12%, showing continued pressure from illicit trade.
Sep.04
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia’s tobacco excise debate is increasingly exposing differences within the governing Labor Party. New South Wales Labor Premier Chris Minns reaffirmed on September 8 that he supports reducing tobacco excise, arguing that current tax settings are pushing consumers toward cheaper black-market cigarettes. Federal Health Minister Mark Butler continues to oppose an excise cut, while Treasurer Jim Chalmers and Assistant Treasurer Daniel Mulino have recently stopped short of ruling out future changes. The divergence follows the opposition Coalition’s proposal to cut tobacco excise by 80%.
Sep.08
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07